Winton Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-7,700
Closed -$434K 1312
2026
Q1
$434K Buy
+7,700
New +$501K 0.02% 749
2023
Q2
Sell
-3,485
Closed -$288K 910
2023
Q1
$288K Buy
+3,485
New +$282K 0.02% 826
2021
Q4
Sell
-25,517
Closed -$1.8M 1174
2021
Q3
$1.8M Sell
25,517
-3,316
-12% -$209K 0.1% 227
2021
Q2
$1.92M Buy
28,833
+14,090
+96% +$997K 0.1% 204
2021
Q1
$1.64M Buy
14,743
+2,290
+18% +$283K 0.09% 212
2020
Q4
$1.48M Sell
12,453
-18,033
-59% -$1.94M 0.11% 221
2020
Q3
$2.66M Buy
30,486
+2,597
+9% +$227K 0.09% 394
2020
Q2
$2.5M Sell
27,889
-3,367
-11% -$340K 0.06% 538
2020
Q1
$3.12M Buy
31,256
+9,892
+46% +$1.07M 0.08% 423
2019
Q4
$2.46M Sell
21,364
-9,352
-30% -$1.13M 0.03% 724
2019
Q3
$3.88M Buy
30,716
+193
+0.6% +$24.5K 0.05% 383
2019
Q2
$3.67M Buy
+30,523
New +$3M 0.07% 232
2018
Q2
Sell
-8,371
Closed -$612K 1077
2018
Q1
$612K Sell
8,371
-99,353
-92% -$6.82M 0.02% 681
2017
Q4
$6.26M Buy
+107,724
New +$5.67M 0.18% 162

Other funds holding HAE

Winton Group's HAE Position: Q2 2026 in Review

Winton Group sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 7,700 shares — an estimated $434K sold.

Winton Group first reported a position in HAE in Q4 2017 and held it in 14 quarters. The position peaked at $6.26M in Q4 2017. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Winton Group reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 7,700 Haemonetics shares in Q2 2026, an estimated $434K.
  • Winton Group first reported a position in Haemonetics in Q4 2017 and held it in 14 quarters.
  • Winton Group's Haemonetics position peaked at $6.26M in Q4 2017.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.